Inhibition of METTL3 Activates Innate Immunity Pathways & Reshapes the Tumor Microenvironment

Time: 3:30 pm
day: Conference Day 1


  • STC-15 is a potent and selective inhibitor of the RNA methyltransferase METTL3, currently evaluated in a First-in-Human Phase I clinical trial
  • STC-15 leads to formation of dsRNA and induces cancer intrinsic type-I interferon response
  • Ex-vivo and in-vivo efficacy studies in preclinical models demonstrate an immune based MoA leading to a long term tumour regression and generating durable immune memory